Twelve monoclonal antibodies were developed which show selective reactivity with brain tissue homogenates from 4 patients with schizophrenia compared to 4 normal controls. Certain antibodies were more reactive with tissue from cases with schizophrenia, others with control tissue. Patterns of reactivity also depended on brain region tested. Differences in reactivity generally ranged from 2- to as much as 8-fold. This panel of monoclonal antibodies may be useful to investigate the pathophysiology of schizophrenia.